Abstract:Background: Breast cancer risk prediction is often based on clinicopathological characteristics despite the high heterogeneity derived from gene expression. Metabolic alteration is a hallmark of cancer, and thus, the integration of a metabolic signature with clinical parameters is necessary to predict disease outcomes in breast cancers. Methods: Metabolic genes were downloaded from the Gene Set Enrichment Analysis (GSEA) dataset. Genes with statistical significance in the univariate analysis were applied in the least absolute shrinkage and selection operator (LASSO) analysis to build a gene signature in the GSE20685 dataset. Clinicopathological characteristics and risk scores with prognostic significance were incorporated into the nomogram to predict the overall survival (OS) of patients. The Cancer Genome Atlas (TCGA) and GSE866166 datasets were used as the validation datasets. Time-dependent receiver operating characteristic (tROC) curves and calibration plots were used to assess the accuracy and discrimination of the model. Results: A 55-gene metabolic gene signature (MGS) was constructed, and was significantly related to OS both in the discovery (P<0.001) and validation (P<0.001) datasets. The MGS was an independent prognostic factor and could divide patients into high-and low-risk groups regardless of their different prediction analysis of microarray 50 (PAM50) subtypes. Time-dependent ROC curves indicated that the risk scores based on the MGS [area under the ROC curve (AUC): 0.931] were superior to the those based on the American Joint Committee on Cancer (AJCC) stage (AUC: 0.781) and PAM50 (AUC: 0.675). A nomogram based on the AJCC stage and risk score could predict OS, and the calibration curves showed good agreement to the actual outcome, indicating that the nomogram may have practical utility. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analysis indicated that this MGS was primarily enriched in amino acid pathways. Conclusions: Our results demonstrated that the MGS was superior to existing risk predictors such as PAM50 and AJCC stage. By combining clinical factors (AJCC stage) and the MGS, a nomogram was constructed and showed good predictive ability for OS in breast cancer.

A Novel Seventeen-Gene Metabolic Signature for Predicting Prognosis in Colon Cancer

Development and validation of a metabolic gene signature for predicting overall survival in patients with colon cancer

Identification and Validation of a Metabolism-Related Gene Signature for the Prognosis of Colorectal Cancer: a Multicenter Cohort Study

A Novel Coiled-Coil Domain Containing-Related Gene Signature for Predicting Prognosis and Treatment Effect of Breast Cancer.

Construction and validation of a metabolic risk model predicting prognosis of colon cancer

Proteomic Profiling Reveals a Signature for Optimizing Prognostic Prediction in Colon Cancer

Development and Validation of a Novel Epigenetic Signature for Predicting Prognosis in Colon Cancer.

Identification of a Four-Gene Metabolic Signature to Evaluate the Prognosis of Colon Adenocarcinoma Patients

A Novel Metabolism-Related Prognostic Gene Development and Validation in Gastric Cancer.

A Metabolic Gene Signature to Predict Breast Cancer Prognosis

Construction and Validation of Four-Metabolism Related-Long Non-Coding RNAs As Potential Signature in Prognosis of Colon Cancer

Prognostic implications of metabolism-associated gene signatures in colorectal cancer

Development and Validation of Metabolism-Related Gene Signature in Prognostic Prediction of Gastric Cancer

Identification of sixteen metabolic genes as potential biomarkers for colon adenocarcinoma

A novel metabolic-related gene signature for predicting clinical prognosis and immune microenvironment in head and neck squamous cell carcinoma

Identification of Metabolic Genes for the Prediction of Prognosis and Tumor Microenvironment Infiltration in Early-Stage Non-Small Cell Lung Cancer.

A Novel Metabolic Gene Signature-Based Nomogram to Predict Overall Survival in Breast Cancer

A Metabolism-Relevant Signature As a Predictor for Prognosis and Therapeutic Response in Pancreatic Cancer.

Development And Validation Of A Metabolic Gene-Based Prognostic Signature For Hepatocellular Carcinoma

A Metabolism-Associated Gene Signature for Prognosis Prediction of Hepatocellular Carcinoma

A Systematic Analysis of a Potential Metabolism-Related Prognostic Signature for Breast Cancer Patients